Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

-- FIRST PATIENT DOSED IN ELEVATE-44-201 WITH DATA FROM FIRST PATIENT COHORT ANTICIPATED IN H1 2026 -- -- INITIATED ELEVATE-45-201 AND ON TRACK TO DOSE THE FIRST PATIENT IN Q3 2025 -- -- MULTIPLE CLINICAL TRIAL SITES IN U.K. AND EU ACTIVATED FOR ELEVATE-44-201 AND ELEVATE-45-201 -- -- LEADERSHIP TEAM EXPANDED WITH THE ADDITIONS OF NAVID KHAN, PHD, AS SENIOR VICE PRESIDENT OF MEDICAL AFFAIRS AND KIRAN PATKI, MD, MSC, FFPM, AS SENIOR VICE PRESIDENT OF CLINICAL DEVELOPMENT -- -- CASH RUNWAY EXPECTED INTO Q2 2027 WITH $354 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2025 -- BOSTON, AUG. 06, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND HIGHLIGHTED RECENT BUSINESS UPDATES. NOW, MORE THAN EVER, PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY NEED SAFER AND EFFICACIOUS THERAPEUTIC OPTIONS.

ENTRADA THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

BOSTON, JUNE 03, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED THE APPOINTMENT OF MAHA RADHAKRISHNAN, M.D., TO ITS BOARD OF DIRECTORS.

ENTRADA THERAPEUTICS APPOINTS MAHA RADHAKRISHNAN, M.D., TO ITS BOARD OF DIRECTORS

BOSTON, JUNE 02, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED THAT THE COMPANY GRANTED AN AGGREGATE OF 23,820 RESTRICTED STOCK UNITS (RSUS) TO SIX NEWLY-HIRED NON-EXECUTIVE EMPLOYEES UNDER THE COMPANY'S 2025 INDUCEMENT EQUITY PLAN (THE INDUCEMENT PLAN), EFFECTIVE AS OF JUNE 1, 2025. THE INDUCEMENT GRANTS WERE PREVIOUSLY APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS, AS A MATERIAL INDUCEMENT TO THE NEW EMPLOYEES' ENTRY INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ENTRADA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

 COMPANY ON TRACK TO BEGIN ELEVATE-45-201 IN Q3 2025   FOLLOWS RECENTLY RECEIVED MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AUTHORIZATION IN THE UNITED KINGDOM FOR ELEVATE-45-201  BOSTON, MAY 28, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED IT HAS RECEIVED AUTHORIZATION FROM THE HEALTH AUTHORITIES AND ETHICS COMMITTEES OF MULTIPLE COUNTRIES UNDER THE EUROPEAN UNION CLINICAL TRIAL REGULATION (EU-CTR) TO INITIATE ELEVATE-45-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE (MAD) CLINICAL STUDY OF ENTR-601-45 IN PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) WHO ARE AMENABLE TO EXON 45 SKIPPING. ELEVATE-45-201 IS THE MOST ADVANCED CLINICAL STUDY OF A CONJUGATED EXON SKIPPING THERAPY FOR INDIVIDUALS AMENABLE TO EXON 45 SKIPPING AND OFFERS THE POTENTIAL TO ADDRESS A LARGE DUCHENNE SUBPOPULATION WITH SIGNIFICANT UNMET MEDICAL NEEDS, SAID DIPAL DOSHI, CHIEF EXECUTIVE OFFICER AT ENTRADA THERAPEUTICS.

ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE EUROPEAN UNION TO INITIATE ELEVATE-45-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-45 IN PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO EXON 45 SKIPPING

 RECEIVES REGULATORY AUTHORIZATION IN THE EU FOR ELEVATE-44-201, A PHASE 1/2 MAD CLINICAL STUDY OF ENTR-601-44 IN PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY WHO ARE AMENABLE TO EXON 44 SKIPPING   COMPANY REMAINS ON TRACK TO INITIATE ELEVATE-44-201 AND ELEVATE-45-201 IN Q2 AND Q3 2025, RESPECTIVELY   CASH RUNWAY EXPECTED INTO Q2 2027 WITH $383 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2025  BOSTON, MAY 08, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND HIGHLIGHTED RECENT BUSINESS UPDATES. WE ARE EXCITED TO ANNOUNCE THE FIRST EUROPEAN UNION REGULATORY CLEARANCE WITHIN OUR DUCHENNE FRANCHISE, WITH THE AUTHORIZATION TO INITIATE THE ELEVATE-44-201 PATIENT STUDY ACROSS MULTIPLE COUNTRIES.

ENTRADA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

 COMPANY ON TRACK TO INITIATE ELEVATE-45-201 STUDY IN Q3 2025   ELEVATE-45 REGULATORY FILINGS SUBMITTED IN THE EU, WITH REGULATORY REVIEW ONGOING   ELEVATE-45 IS THE SECOND OF THREE NOVEL EXON SKIPPING DUCHENNE PROGRAMS THE COMPANY EXPECTS TO PROGRESS INTO GLOBAL CLINICAL DEVELOPMENT IN 2025  BOSTON, MARCH 24, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED IT HAS RECEIVED AUTHORIZATION FROM THE UNITED KINGDOM'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AND RESEARCH ETHICS COMMITTEE TO INITIATE ELEVATE-45-201. ELEVATE-45-201 IS A PHASE 1/2 MULTIPLE ASCENDING DOSE (MAD) CLINICAL STUDY TO EVALUATE ENTRADA'S INVESTIGATIONAL MEDICINAL PRODUCT ENTR-601-45 FOR THE POTENTIAL TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WITH A CONFIRMED MUTATION IN THE DMD GENE AMENABLE TO EXON 45 SKIPPING.

ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE UNITED KINGDOM TO INITIATE ELEVATE-45-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-45 IN PEOPLE LIVING WITH DUCHENNE MUSCULAR DYSTROPHY AMENABLE TO EXON 45 SKIPPING

 RECEIVED FDA AUTHORIZATION TO INITIATE ELEVATE-44-102 IN THE U.S.   RECEIVED MHRA AUTHORIZATION TO INITIATE ELEVATE-44-201 IN THE U.K.   SUBMITTED REGULATORY FILINGS TO SUPPORT GLOBAL CLINICAL STUDIES FOR ENTR-601-44 IN THE EU, AND ENTR-601-45 IN THE U.K. AND EU   CASH RUNWAY EXPECTED INTO Q2 2027 WITH $420 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2024  BOSTON, FEB. 27, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024 AND HIGHLIGHTED RECENT BUSINESS UPDATES. WE ARE THRILLED TO BEGIN 2025 WITH SIGNIFICANT MOMENTUM.

ENTRADA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

 RECEIVES FDA AUTHORIZATION TO INITIATE ELEVATE-44-102, A PHASE 1B MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-44 IN ADULTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY   FOLLOWS RECENTLY RECEIVED MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AUTHORIZATION IN THE UNITED KINGDOM FOR ELEVATE-44-201   EXPANDS GLOBAL ELEVATE-44 CLINICAL PROGRAM TO INCLUDE PEDIATRIC, ADULT, AMBULATORY AND NON-AMBULATORY PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY  BOSTON, FEB. 24, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED THAT THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS LIFTED THE CLINICAL HOLD ON ENTR-601-44 AND PROVIDED AUTHORIZATION TO INITIATE ELEVATE-44-102, A PHASE 1B MULTIPLE ASCENDING DOSE (MAD) CLINICAL STUDY OF ENTR-601-44 FOR THE POTENTIAL TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN ADULT PATIENTS WITH A CONFIRMED MUTATION IN THE DMD GENE AMENABLE TO EXON 44 SKIPPING. THE GLOBAL ELEVATE-44 PROGRAM, WHICH INCLUDES THE ELEVATE-44-102 STUDY IN THE U.S. AND ELEVATE-44-201 OUTSIDE OF THE U.S., WILL COVER A BROAD POPULATION OF PATIENTS WITH DMD AND SUPPORT EVALUATION OF ENTR-601-44 IN PATIENTS WITH BOTH EARLY AND ADVANCED DISEASE.

ENTRADA THERAPEUTICS ANNOUNCES FDA REMOVAL OF CLINICAL HOLD ON ENTR-601-44

 COMPANY ON TRACK TO INITIATE ELEVATE-44-201 IN Q2 2025   ENTR-601-44 REGULATORY FILINGS SUBMITTED IN ADDITIONAL GEOGRAPHIES INCLUDING THE U.S. AND EU, WITH REGULATORY DISCUSSIONS ONGOING  BOSTON, FEB. 03, 2025 (GLOBE NEWSWIRE) -- ENTRADA THERAPEUTICS, INC. (NASDAQ: TRDA) TODAY ANNOUNCED IT HAD RECEIVED AUTHORIZATION FROM THE UNITED KINGDOM'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) AND RESEARCH ETHICS COMMITTEE FOR ITS CLINICAL TRIAL OF AN INVESTIGATIONAL MEDICINAL PRODUCT TO INITIATE ELEVATE-44-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE (MAD) CLINICAL STUDY OF ENTR-601-44 FOR THE POTENTIAL TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WITH A CONFIRMED MUTATION IN THE DMD GENE AMENABLE TO EXON 44 SKIPPING. THE CLEARANCE BY THE MHRA MARKS A NEW PHASE IN ENTRADA'S GROWTH AND, MOST IMPORTANTLY, MOVES US CLOSER TO REALIZING OUR COMMITMENT TO FAMILIES LIVING WITH DUCHENNE MUSCULAR DYSTROPHY, SAID DIPAL DOSHI, CHIEF EXECUTIVE OFFICER OF ENTRADA THERAPEUTICS.

ENTRADA THERAPEUTICS RECEIVES AUTHORIZATION IN THE UNITED KINGDOM TO INITIATE ELEVATE-44-201, A PHASE 1/2 MULTIPLE ASCENDING DOSE CLINICAL STUDY OF ENTR-601-44 IN PATIENTS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY

BURLINGTON, MASS. , JAN. 30, 2025 /PRNEWSWIRE/ -- AZENTA, INC. (NASDAQ: AZTA) TODAY ANNOUNCED THAT DIPAL DOSHI, CHIEF EXECUTIVE OFFICER OF ENTRADA THERAPEUTICS (NASDAQ: TRDA) AND A RECOGNIZED LEADER IN THE BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRIES, HAS BEEN ELECTED TO ITS BOARD OF DIRECTORS AT ITS ANNUAL MEETING OF STOCKHOLDERS HELD EARLIER TODAY.

Entrada Therapeutics, Inc.

TRDA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Entrada Therapeutics, Inc.

TRDA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TRDA